Marilyn Tavenner, president and CEO of America’s Health Insurance Plans, believes that while the tone of this year’s presidential election race has been interesting, the discussion among the candidates regarding issues of healthcare and coverage have generally been the same as elections in years past.
Marilyn Tavenner, president and CEO of America’s Health Insurance Plans, believes that while the tone of this year’s presidential election race has been interesting, the discussion among the candidates regarding issues of healthcare and coverage have generally been the same as elections in years past.
Transcript (slightly modified):
How much does a presidential election weigh on the minds of AHIP’s members? And is this election any different?
Well I think every time there’s an election, members are looking to see what is going to be the healthcare strategy of the presidential candidate. In this case, I think that we understand if you’re talking about Secretary Clinton, she’s been pretty clear about continuing to grow the ACA, making some improvements in the ACA, dealing with delivery system reform. Likewise, for Donald Trump, there’s been less detail but certainly there’s a Republican house we work closely with and they are in the process of putting together principles around healthcare strategy and many of those we endure such as delivery system reform and continuing coverage and quality improvements.
So probably not a lot different than — while the tone of this election’s certainly been more interesting, probably the issues are the same.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More